Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM and HbA1C ≤7.5% on ≤1 non-insulin hypoglycemic agent or HbA1C ≤7.0% on ≤2 non-insulin hypoglycemic agents admitted to the hospital for a non-critical illness.~* Written informed consent.~Exclusion Criteria:~* Admitted to or expected to require admission to ICU~* Patients with a history of diabetic ketoacidosis or hyperosmolar state~* HbA1c \>7.5% at the time of admission or within 3 months before admission~* Insulin requiring before admission~* Unable to take oral food or medications~* Systemic steroid use~* Pregnancy or breastfeeding~* Women of Child-Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 4 weeks after the last dose of study drug.~* History of pancreatitis or active gallbladder disease~* End stage renal disease on dialysis~* Hypersensitivity to saxagliptin or another contraindication to DPP4 inhibitors~* Subject unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin group (Type: EXPERIMENTAL): DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
- Standard therapy group (Type: NO_INTERVENTION): Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).